Comparison of Prevalence of Chalazion among Diabetic and Non-Diabetic Patients
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.256 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Leena Saxena und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Chalazion usually defined as a localized continual granulomatous infection of the meibomian glands, generally affecting the upper eyelids. Diabetes is being a chronic metabolic disorder, often associated with significant morbidity and mortality in multiple systems of the body. DM affects nervous system (diabetic neuropathy), kidney (nephropathy), immune system (cause of recurrent infections), eye and various other systems. In our study we investigated patients with presenting complaints of chalazion for their diabetic status and stratified them into two groups diabetic and non-diabetic. Both groups treated with same protocol and procedures and analysis compared. As a result, we found that non-diabetic patients take less time to recover compared to poorly controlled diabetic patients.
Zitieren
APA
Saxena, L., Jain, J. K., & Singh, D. P. (2026). Comparison of Prevalence of Chalazion among Diabetic and Non-Diabetic Patients. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.256
Vancouver
Saxena L, Jain JK, Singh DP. Comparison of Prevalence of Chalazion among Diabetic and Non-Diabetic Patients. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.256
BibTeX
@article{Saxena2026,
author = {Saxena, Leena and Jain, Jitendra Kumar and Singh, Dushyant Pal},
title = {Comparison of Prevalence of Chalazion among Diabetic and Non-Diabetic Patients},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.256}
}
EUVIMED